Crizotinib price adjustment and decline analysis in 2025

Crizotinib is a typical targeted therapy drug that mainly acts on patients with ALK-positive and ROS1-positive non-small cell lung cancer (NSCLC). As a first-generation ALK inhibitor, it slows the growth of cancer cells and inhibits tumor spread by inhibiting tumor cell signaling pathways. Since its introduction, crizotinib has brought important changes to the treatment landscape of lung cancer worldwide, and is still recommended in many guidelines as the first-line treatment option for patients with ALK or ROS1 rearrangement-positive patients.

In China, the original drug of crizotinib has been on the market for many years and has entered the national medical insurance drug catalog, which greatly eases the financial burden of patients. Common specifications currently include 250mg 60 capsules and 200mg 60 capsules. The price of each box may exceed 10,000 yuan before reimbursement. After medical insurance negotiation, patients who meet the indications can enjoy partial or even substantial cost reductions. The continuous optimization of medical insurance policies has enabled more and more patients to afford such targeted drugs, thus improving the overall survival rate and treatment compliance.

From the international market, the pricing of the original drug of crizotinib is relatively stable. The price per box is still around RMB 10,000, which may fluctuate due to exchange rate fluctuations. However, with the gradual expiration of patent protection periods and the emergence of generic drugs, market prices have shown a clear downward trend. Especially in countries such as Bangladesh and Laos, there are already cost-effective imitation versions produced by multiple manufacturers. The specifications are also 250mg*60 capsules, and each box sells for only about 1,000 yuan. These generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, so they have gradually become the main choice for some overseas patients.

In the future, as more similar ALK inhibitors enter the reimbursement list and generic drugs expand globally, the market price of crizotinib is expected to remain stable with a slight decrease, thus further benefiting the majority of cancer patients.

Reference materials:https://go.drugbank.com/drugs/DB08865